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Synthetic cathinones are new stimulant drugs derived from cathinone that have 
been sold as “legal highs” worldwide. These compounds can elicit powerful 
effects such as delusions, hallucinations as well as other potentially dangerous 
behavior. New analogs with varying effects and potencies are constantly 
introduced in the market to evade legislation, and they are not detected by 
routine screening and confirmation methods. Oral fluid is an alternative matrix of 
increasing interest in forensic toxicology. Its collection is non-invasive and easily 
supervised, and positive drug findings typically reflect recent drug exposure. The 
focus of this research was to develop a method for the determination of 10 
synthetic cathinones (cathinone, methcathinone, buphedrone, mephedrone, 4-
methylethcathinone, 3,4-methylenedioxypyrovalerone (MDPV), methylone, 
naphyrone, alpha-pyrrolidinovalerophenone (PVP) and N-ethylcathinone) in 
preserved oral fluid (QuantisalTM), as well as evaluate their stability in preserved 
(Quantisal and Oral-EzeTM) and neat oral fluid samples stored under different 
conditions, using ultrahigh-performance liquid chromatography–tandem mass 
spectrometry (UHPLC-MSMS). Four-hundred μL oral fluid-Quantisal buffer 
mixture (100 μL oral fluid and 300 μL buffer) were subjected to cation exchange 
solid phase extraction. The chromatographic reverse-phase separation was 
achieved with a gradient mobile phase of 0.1 % formic acid in water and in 
acetonitrile in 5 min.  We used a Shimadzu triple quadrupole mass spectrometer 
in multiple reaction monitoring (MRM) mode. The assay was linear from 1-250 
ng/mL, with the limits of detection of 0.75-1 ng/mL. Imprecision (n=15) was 
<20.7% and accuracy (n=15) was 84-115.3%. Extraction efficiency was 87.2-
116.8% (n=6), process efficiency was 30.9-103.7% (n=6), and matrix effect was -
65.1 to -6.2% (CV 2.5-15.1%, n=6). The stability was performed for neat oral 
fluid, oral fluid in Quantisal buffer, and oral fluid in Oral-Eze buffer samples 
stored up to one month at room temperature, 4oC and -20oC, and after 3 freeze-
thaw cycles. Losses up to -71.2 to -100% were observed in neat and preserved 
samples stored at room temperature up to one month. At 4oC, losses up to -
88.2% occurred in neat OF and Oral-Eze samples, while Quantisal samples 
showed losses up to -34%. All types samples were stable if stored at -20oC and 
after 3 freeze-thaw cycles.  
 






Synthetic cathinones are novel psychoactive substances (NPS) that can elicit 
powerful effects such as delusions, hallucinations and potentially dangerous 
behavior [1]. Since the mid-2000s, synthetic cathinones gained popularity in the 
recreational drug market worldwide because of their unregulated status, low cost 
and ready accessibility via the Internet and head shops [2]. They are advertised 
as “legal highs” and sold as “bath salts” or “plant food”, and are labeled as “not 
for human consumption” to avoid drug abuse legislation [3]. Constantly new 
synthetic cathinones are synthesized to circumvent existing laws on controlled 
substances, and/or to enhance pharmacological activity.   
Synthetic cathinones are derivatives of cathinone, a naturally occurring 
beta-ketone amphetamine analogue found in the leaves of the Catha edulis 
plant. Synthetic cathinones are phenylalkylamines derivatives, and are often 
termed “bk-amphetamines” for the beta-ketone component [4]. The main 
cathinone derivative classes are position 3’-substitiuted (buphedrone), ring-
substituted (mephedrone), N-alkyl-substituted (ethylcathinone), methylenedioxy-
substituted (methylone), and pyrrolidinyl-substituted (3’,4’-
methylenedioxypyrovalerone (MDPV)). These derivative classes are illustrated in 
Figure 1.  
Synthetic cathinone pharmacological effects may be similar to those of 
cocaine, amphetamine or (±)-3,4-methylenedioxymethamphetamine (MDMA), 
depending upon the class [3]. Desired effects reported by users of synthetic 
cathinones were increased energy, empathy, openness, and increased libido. 
Cardiac, psychiatric, and neurological signs and symptoms are the most common 
adverse effects reported in synthetic cathinone users who require medical care 
[4].  
Currently, bupropion is the only cathinone derivative that carries a medical 
indication in the US and Europe [4]. It is prescribed for the treatment of 
depression and as a smoking-cessation aid. Only cathinone and methcathinone 
were listed as Schedule I drugs, with diethylcathinone and pyrovalerone as 
Schedule IV of the United Nations 1971 Convention on Psychotropic 
Substances.  As a consequence of synthetic cathinones’ abuse potential, 
mephedrone, MDPV and methylone were permanently controlled as Schedule I 
drugs in the United States Controlled Substances Act in 2013 [3]. Ten additional 
cathinones were temporarily scheduled as class I drugs in 2014, 4-
methylethcathinone (4-MEC), 4-methyl-α-pyrrolidinopropiophenone (4-MPPP), α-
pyrrolidinopentiophenone (α -PVP), butylone, pentedrone, pentylone, 4-
fluoromethcathinone (4-FMC), 3-fluoromethcathinone (3-FMC), naphyrone, and 
α-pyrrolidinobutiophenone (α -PBP) in 2014 [5], and extended for another year in 
2016 [6]. Although many other cathinone derivatives are not yet under 
international control, restrictive legislation has been introduced in multiple 
countries.  
Oral fluid is an alternative matrix that has increasing interest in forensic 
and clinical toxicology. Its collection is non-invasive and easily supervised, and 
its window of detection may be similar to blood indicating recent drug exposure 
[7]. However, the use of oral fluid may pose analytical challenges because the 
sample volume is low (<1mL), drug concentrations are much lower (low ng/mL) 
than in urine (ng/mL and μg/mL) and salivation may be reduced after the intake 
of drugs with sympathomimetic properties [7].  
There are different devices available for oral fluid collection. The general 
procedure consists of a swab or pad that is inserted into the mouth to draw the 
oral fluid. The swab or pad is then placed into a vial that contains a buffer to 
preserve the sample [1]. Examples of the most common commercially available 
oral fluid devices are QuantisalTM (Immunalysis Corp., Pomona, CA, USA) and 
Oral-Eze® (Capitol Vial, Inc., Auburn, AL, USA). These devices employ different 
buffers to improve the stability of the compounds in oral fluid samples and to 
avoid bacterial growth.  
Several articles described analytical methods for the determination of 
synthetic cathinones in urine and blood/plasma [8]; however, only two 
confirmation methods have been published in oral fluid [1, 9]. Amaratunga et al. 
[1] developed a method for the determination of 10 synthetic cathinones in 400 
μL of oral fluid-Quantisal buffer mix, achieving a limit of quantification of 1 ng/mL. 
De Castro et al. [9] developed a method for the determination of 5 synthetic 
cathinones in 500 μL of neat oral fluid, achieving a limit of quantification of 0.2 
ng/mL. Both methods were developed by liquid chromatography tandem mass 
spectrometry (LC-MSMS).  
Information about stability of drugs in biological samples is critical for accurate 
interpretation of analytical results. Many times biological specimens cannot be 
assayed immediately after collection due to laboratory workload, instrumentation 
downtime, shipment delay, or if a second analysis or a counter-test is requested 
after some time. This delay in the anlaysis can be problematic if the analytes are 
not stable in the biological samples. Although synthetic cathinones stability is 
compromised in blood and urine [3, 10-15], few data are available in oral fluid [9]. 
De Castro et al. [9] showed that cathinones were stable in neat oral fluid and in 
Quantisal buffer samples at 4°C for 24 h and after 3 freeze-thaw cycles. Long-
term information (> 24h) or stability data in other collection buffers is not currently 
available.  
We developed a method for the determination of 10 synthetic cathinones 
in preserved oral fluid (Quantisal) by ultrahigh-performance liquid 
chromatography–tandem mass spectrometry (UHPLC-MSMS) to evaluate 
synthetic cathinones’ stability in preserved (Quantisal and Oral-Eze) and in neat 
oral fluid fortified samples stored under different conditions (room temperature, 
4°C and -20°C) from 24 h to one month and after 3 freeze-thaw cycles. 
  
Methods and Materials 
 
Chemicals and Materials 
 
Cathinone, methcathinone, methylone, N-ethylcathinone, buphedrone, 
mephedrone, 4-methylethcathinone, α-pyrolidinovarophenone (PVP), MDPV, and 
naphyrone (1 mg/mL), and internal standards MDPV-d8, mephedrone-d3, 
methylone-d3, and naphyrone-d5 (100 µg/mL) were obtained from Cerilliant 
(Round Rock, TX, USA).  Solid phase extraction (SPE) cation exchange 
cartridges Strata Drug-X B 60 mg/3 mL were from Phenomenex (Torrance, CA, 
USA). Glacial acetic acid, acetonitrile, ammonium hydroxide, and formic acid 
were acquired from Pharmco-Aaper (Shelbyville, KY, USA). Methanol, 
dichloromethane, and isopropanol were acquired from Fisher Scientific 
(Pittsburgh, PA, USA). All solvents used in the extraction were high performance 
liquid chromatography (HPLC) grade and in the chromatographic instrument 
were liquid chromatography- mass spectrometry (LC-MS) grade. Quantisal buffer 
was obtained from Immunalysis Corp. (Pomona, CA, USA) and Oral-Eze buffer 
from Capitol Vial, Inc. (Auburn, AL, USA). Neat drug-free OF was obtained from 





Ultrahigh-performance liquid chromatography–tandem mass spectrometry 
(UHPLC-MSMS) instrument was from Shimadzu (Columbia, MD, USA). The 
Nexera UHPLC system consisted of a binary LC-20ADXR HPLC pump, Nexera 
LC-30AD micro mixer, online degassing unit DGU-20A3R and cooled 
autosampler SIL-20SCHT UFLC. The mass spectrometer was a triple 
quadrupole LC-MS 8030 equipped with Dual Ionization Source (DUIS). SPE was 
performed using a negative pressure manifold from Fisher Scientific. Evaporation 
under nitrogen was completed using TurboVap LV from Biotage (Charlotte, NC, 
USA). 
 
Preparation of Standard Solutions 
 
Calibrators’ working solutions at 4, 10, 20, 100, 200, 400 and 1000 ng/mL were 
prepared by appropriate dilution in methanol. Controls’ working solutions at 12 
ng/mL (low) and 600 ng/mL (high) were prepared in methanol. The combined 
internal standard solution (MDPV-d8, mephedrone-d3, methylone-d3, and 
naphyrone-d5) at 100 ng/mL was prepared in methanol. All solutions were stored 
in amber vials at -20°C. 
 
Preparation of calibrators and controls samples 
 
The calibrators were prepared spiking the calibrators’ working solutions in drug-
free OF-buffer mixtures (0.1 mL OF and 0.3 mL Quantisal buffer).  
The controls were prepared spiking the controls’ working solutions in drug-free 
OF-buffer mixtures (0.1 mL OF and 0.3 mL Quantisal buffer; 0.1 mL OF and 0.2 
mL Oral-Eze buffer) and 0.1 mL neat OF.  
Quantisal and Oral-Eze buffer volumes were selected based on the 
OF/Buffer ratio of the collection devices. Quantisal devices collect 1 mL oral fluid 
and contain 3 mL of buffer (1/3, OF/Buffer ratio). Oral-Eze devices also collect 1 
mL of oral fluid, but contain 2 mL of buffer (1/2, OF/Buffer ratio). 
Stability study design 
 
Two pools of stability samples at low (2.5 ng/mL) and high (150 ng/mL) 
concentrations were prepared in neat OF, OF-Quantisal and OF-Oral-Eze 
mixtures. Each pool was prepared using a total of 5 mL of OF from 5 different 
donors (1 mL each). 5 mL of blank OF, 5 mL of OF and 15 mL Quantisal buffer, 
and 5 mL of OF and 10 mL Oral-Eze buffer were fortified with 12.5 μL of a 
standards mixture at 1 μg/mL (low concentration) or with 75 μL of a standards 
mixture at 10 μg/mL (high concentration). The different pools were vortexed for 1 
min and split in 18 aliquots (9 conditions by duplicate) in 2 mL polypropylene 
cryotubes (Fisher Scientific) and stored in the dark at room temperature, 4°C and 
-20°C for 24 h, one week and one month. A group of aliquots was submitted to 3 
freeze and thaw cycles. The pH of each pool was measured by pH indicator 
strips colorpHast® pH 0-14 from EM Science (Darmstadt, Germany).   
. 
Oral fluid analysis 
 
Two mL of 1M acetic acid and 25 uL of internal standard solution at 100 ng/mL 
were combined with 0.4 mL OF-Quantisal, 0.3 mL OF-Oral-Eze, or 0.1 mL neat 
OF, and gently vortexed. The samples were then loaded onto Strata Drug-X B 
cartridges that were conditioned with 2 mL methanol and 2 mL deionized water. 
The cartridges were washed first with 2 mL of 1M acetic acid, then with 2 mL 
methanol. The cartridges were dried under vacuum for 10 min. The elution was 
done by 2 mL of 2% ammonium hydroxide in dichloromethane:isopropanol (95:5, 
v/v).  Before evaporation, 100 μL of 1% HCl in methanol was added to prevent 
synthetic cathinones’ loss. Evaporation was performed under a stream of 
nitrogen at 40°C in a TurboVap LV evaporator. The dried samples were 
reconstituted with 100 μL of 0.1% formic acid in water and vortexed briefly. The 
samples were transferred to screw top auto sampler vials, which contained glass 




Chromatographic separation was accomplished using a Kinetex C18 100x2.1 
mm 1.7μm column (Phenomenex, Torrance, CA, USA) and a gradient method. 
The gradient method employed mobile phase A (0.1% formic acid in water) and 
mobile phase B (0.1% formic acid in acetonitrile) at a flow rate of 0.4 mL/min at 
35°C.  The initial composition of mobile phase B was 2% and was held for 2 
minutes, and then it was increased from 2 to 95% over 8 minutes, it was held at 




The triple quadrupole mass spectrometer (LCMS-8030) was equipped with Dual 
Ionization Source (DUIS) and operated in the positive ionization mode. The spray 
voltage was 4.5 kV, corona pin voltage was 4.5 kV, desolvation line (DL) 
temperature 250 °C, heat block temperature 400 °C, nebulizing gas flow rate 2 
L/min, and dry gas flow rate 15 L/min. Each compound was monitored by 2 
transitions in multiple reaction monitoring mode (MRM). These parameters are 
summarized in Table 1.   
 
Method Validation  
 
The method was validated in OF-Quantisal samples according to SWGTOX 
guidelines [16]. The studied parameters were linearity, limits of detection (LOD) 
and quantification (LOQ), imprecision, accuracy, extraction efficiency, process 
efficiency, matrix effect, carryover, dilution integrity, and autosampler stability. 
Linearity was determined in five different days by least-squares regression with 
1/x2 weighting. The acceptable linearity was accomplished when the r2 
(coefficient of determination) was ≥ 0.99 and the residuals were within ±20%. 
The LOD and LOQ were evaluated with decreasing analyte concentrations in 
drug fortified preserved OF from 3 different sources. The LOD was the lowest 
concentration with acceptable chromatography, signal-to-noise ratio > 3, 
presence of all product ions, correct ion ratio, and a retention time within ±0.2 
minutes of the calibrator retention time. The limit of quantification satisfied the 
LOD criteria and was quantified within ±20% imprecision and 80-120% accuracy.  
The imprecision and accuracy was determined at two concentrations, 3 
ng/mL (low QC) and 150 ng/mL (high QC) in triplicate on five different days 
(n=15).  Imprecision was determined via coefficient of variation (%CV) of the 
measured values and expected to be less than 20%. The pooled intra-day was 
determined by the highest %CV among the five different days (n=15). The total 
imprecision was determined by the average of the %CV over the five days 
(n=15). The accuracy was determined via the percentage of the target 
concentration (n= 15) and was required to be within 80-120%. 
For extraction efficiency at each QC concentration (low and high) blank 
samples were fortified with the appropriate QC solution before and after sample 
extraction. The extraction efficiency was expressed as a percentage of the mean 
analyte area of samples fortified before sample extraction (n = 6) divided by 
mean area of samples fortified after sample extraction (n = 6). To determine 
matrix effect we compared analyte peak areas in blank extracted samples 
fortified with the appropriate QC solutions after sample extraction (n=6) to peak 
areas of neat samples at the same concentrations (n=3). The neat samples were 
prepared by fortifying QC working solutions into 100 μL 1% HCl in methanol. The 
neat samples were then evaporated and reconstituted in 100 μL 0.1% formic acid 
in water. The calculation for determining the matrix effect was (100 × mean peak 
area of fortified samples after extraction/mean peak area of neat samples) -100. 
Process efficiency, overall effect of extraction efficiency and matrix effect on 
quantification of analytes, was expressed as a percentage, which was 
determined by the mean analyte peak areas of sample fortified before extraction 
(n=6) divided by the mean peak areas of neat samples of the same concentration 
(n=3).  
To determine carryover, internal standard fortified blank samples (negative 
calibrator) were injected immediately after samples spiked at 250 ng/mL, the 
highest calibrator concentration. The carryover was considered negligible if the 
measured concentration was less than the LOD. The dilution integrity was 
determined by diluting 500 ng/mL samples to 50 ng/mL, a 1:10 dilution, in 
duplicate. Dilution was performed with blank OF-Quantisal mixture. The dilution 
integrity was maintained if the samples quantified within ±20% of 50 ng/mL. 
Autosampler stability was evaluated reinjecting low and high QC extracts stored 
24 h at 10°C in the autosampler. Extracts were stable if quantified within 20% of 
the QC target value. 
 
Identification Criteria  
 
The identification criteria included retention time in the range of ±0.2 minutes of 
the calibrator retention time, the presence of two product ions (quantitative and 
qualitative), and ion ratio between the qualifier and quantifying ion in the range of 




The stability aliquots of neat OF, OF-Quantisal and OF_Oral-Eze were stored at 
room temperature (24 h, 1 week and 1 month), at 4°C (1 week and 1 month), at -
20°C (1 week and 1 month), and submitted to 3 freeze-thaw samples. On the day 
of analysis, internal standard solution was added and samples were analyzed as 
described above. Each sample was analyzed in duplicate. The % difference was 
calculated comparing the mean concentration of the fresh QCs (n=2) and the 
mean concentration of the corresponding QC after a determined storage 
condition (n=2). Stability was considered acceptable if QC samples quantified 
within ±20 % of the freshly prepared pool samples on Day 0 (fresh QCs).  
Neat OF and OF-Oral-Eze samples were quantified using a OF-Quantisal 
calibrators and matched-matrix (neat OF or OF-Oral-Eze) low and high QCs. 






The linearity was verified in OF-Quantisal samples from 1 to 250 ng/mL with a 
1/x2 weighted linear regression in five different days.  The determination 
coefficients (r2) for the set of five calibration curves were 0.99, except for 
cathinone, methcathinone, and PVP, which was 0.98. All analytes showed 
residuals within ±20 %. These results are summarized in Table 2.  The LOD was 
0.75 ng/mL for cathinone, methcathinone, buphedrone, MEC, and PVP, and 1 
ng/mL for methylone, N-ethylcathinone, mephedrone, MDPV, and naphyrone. 
The LOQ was 1 ng/mL for all analytes (Figure 2).   
The imprecision was <20.7% and the accuracy was 84.4–115.3%. The 
extraction efficiencies were from 87.2 to 114.8%, and process efficiencies from 
30.9 to 103.7%. The matrix effects was from -63.8- to -6.2%, with its variation 
being <15.1% (n=6). These results are summarized in Tables 3 and 4.  
No carryover detected after the injection of a sample at 250 ng/mL. The 
processed samples were stable in the autosampler at 10°C 24 h. The dilution 




Synthetic cathinones were not stable in neat oral fluid at room temperature 24 h 
(% difference up to -60.8% at 2.5 ng/mL, -28.8% at 150 ng/mL), one week (up to 
-84.3% at 2.5 ng/mL, -85.2% at 150 ng/mL) and one month (up to -100% at 2.5 
ng/mL, -99.6% at 150 ng/mL). Only MDPV was stable under these conditions (-
3.9 – 18.6% difference). The most unstable cathinones (total loss after one 
month) were cathinone, methcathinone, N-ethylcathinone and naphyrone. At 
4°C, most of synthetic cathinones were stable in neat oral fluid for one week, 
except cathinone, methcathinone and naphyrone (-31.9 - -21.7% loss); however, 
most of them were not stable after a month under these conditions (%loss up to -
88.2%), except PVP and MDPV (-13.4 – 18.6% difference). All cathinones were 
stable in neat OF at -20°C and after 3 freeze-thaw cycles, except naphyrone at 
2.5 ng/mL (-31.2 - -29.6% loss).  
OF samples preserved in Quantisal buffer were stable at room 
temperature for 24 h. After one week, cathinone, methcathinone and naphyrone 
experimented losses up to -37.8% at 2.5 ng/mL, and after one month losses from 
-21.2 to -71.2% were observed for all synthetic cathinones, except for methylone, 
PVP and MDPV. All synthetic cathinones were stable in Quantisal buffer at 4°C 
and -20°C up to one month, except N-ethylcathinone, buphedrone and 
naphyrone at the low concentration 2.5 ng/mL (-34 - -21.6% loss). 
 In Oral-Eze buffer samples, all synthetic cathinones were stable at room 
temperature for 24 h, except cathinone at 2.5 ng/mL (-31.3% loss). Cathinone, 
methcathinone, N-ethylcathinone and naphyrone were not stable after one week 
(% loss up to -58.3%). Only MPDV was stable after one month stored at this 
temperature, while the other cathinones % losses were from -29 to -100%. All 
analytes, except cathinone and naphyrone at low concentration 2.5 ng/mL (-29.7 
- -22.2%), were stable in Oral-Eze at -20°C up to one month and after 3 freeze-
thaw cycles. These results are summarized in Tables 5-7. 
As indicated in the methods and materials section, the % difference was 
calculated comparing the mean concentration of fresh QCs (n=2) and the mean 
concentrations of the stored QCs (n=2). Method’s inaccuracy was not taken into 
consideration for these calculations. Stability data were recalculated taking into 
account the method’s analytical inaccuracy (±15%) in the determination of the 
fresh and stored QC. A maximum and a minimum % difference was calculated. 





A validated method was developed for the determination of 10 synthetic 
cathinones (cathinone, buphedrone, 4- MEC, MDPV, mephedrone, 
methcathinone, methylone, naphyrone, N-ethylcathinone and PVP) in 0.4 mL 
preserved OF-Quantisal samples (0.1 mL neat OF) by UHPLC-MSMS achieving 
1 ng/mL LOQ. The method was applied to study synthetic cathinone stability in 
fortified neat and preserved Quantisal and Oral-Eze OF samples stored at room 
temperature, 4°C and -20°C up to one month, and after 3 freeze/thaw cycles.  
Although the popularity of synthetic cathinones is increasing [17], only two 
OF confirmation methods for synthetic cathinones have been published [1, 9]. 
Amaratunga et al. [1] developed a method for the determination of 10 synthetic 
cathinones (butylone, ethylone flephedrone, MDPV, mephedrone, 
methcathinone, methedrone, methylone, PVP and pyrovalerone) in 0.4 mL of oral 
fluid-Quantisal buffer mix (0.1 mL neat OF), achieving a LOQ of 1ng/mL, similar 
to our method. The method was rapid; the SPE procedure did not involved drying 
steps, and the chromatographic run was 3 min [1]. However, the extraction 
efficiency of lipophilic cathinones such as MDPV, pyrovalerone and PVP, was 
low (around 50 %), and lower than in the present method (106.1-114.1%). De 
Castro et al. [9] developed a method for the determination of 5 synthetic 
cathinones (flephedrone, mephedrone, methylone, pethedrone and MDPV) in 0.5 
mL of neat oral fluid, achieving a LOQ of 0.2 ng/mL. The present method allowed 
the simultaneous confirmation of 10 synthetic cathinones in 0.4 mL of preserved 
OF (0.1 mL neat OF) with 1 ng/mL LOQ. Although De Castro et al. [9] achieved a 
lower LOQ (0.2 ng/mL vs. 1 ng/mL), the amount of sample required was five 
times the amount employed in our method. In OF analysis, the amount of sample 
is limited (normally less than 1 mL). Taking into account the necessity of 
performing different types of test in one sample and that the sample re-analysis 
may be required, the analytical methods should employed the least amount of 
sample as possible that allows a sensitive test. With regard to actual 
concentrations of synthetic cathinones in OF, Amaratunga et al. [1] and De 
Castro et al. [9] applied their methods to authentic oral fluid specimens. Both 
authors reported positive cases for MDPV and PVP with concentrations above 20 
ng/mL. The sensitivity achieved in the present method (LOQ 1 ng/mL) satisfies 
the required sensitivity in these authentic cases. During method development, 
different extraction procedures were evaluated (supported liquid extraction, 
reverse phase SPE, mixed mode SPE, cation exchange SPE and dilute-and-
shoot). Among all of them, cation exchange SPE yielded the best results in terms 
of extraction efficiency, matrix effect and noise level. 
Limited data about NPS stability in biological samples are available. This 
type of data is critical to perform a correct interpretation of analytical results. 
Often there is a delay between sample collection and analysis, and the best 
storage conditions have to be applied until analysis could be performed. Stability 
of synthetic cathinones in urine [3, 10, 11] and in blood/plasma [10, 12-15] has 
been reported; however, OF data is scarce [9]. 
MDPV was reported to be stable in blood at room temperature, 4°C and -
20°C for up to 14 days [10]. Mephedrone, 4-MEC, cathinone, methcathinone, 
ethcathinone and flephedrone showed stability problems in blood samples with 
losses up to 100% [10, 12, 13, 15]. This stability issues were improved if the 
samples were preserved under acidic conditions with NaF/citrate buffer at pH 5.9 
[13] or with NaF/potassium oxalate and at -20°C [15]. As recently reviewed by 
Ellefsen et al. [8], other synthetic cathinones were reported to be stable in blood 
[18, 19], and serum [20] at varying storage conditions (from 24 h to 6 weeks, 
from room temperature to -20°C). In urine, synthetic cathinones showed stability 
problems mainly at room temperature for 14 days [10] or in just 24 h [3]. MPDV 
was reported to be stable under these conditions [3, 10]. Al-Saffar et al. [11] 
reported losses > 40% at -20°C for 3 months for buphedrone, 3-FMC, 4-FMC, 
and pentylone. In OF few data are available [9]. De Castro et al. [9] reported that 
flephedrone, mephedrone, methylone, pethedrone and MDPV were stable in 
neat OF at 4°C for 24 h, and in neat and preserved Quantisal OF after 3 
freeze/thaw cycles. Long term stability (> 24h) and stability in other preserved OF 
samples (Oral-Eze) is not currently available.  
Based on these reported data, synthetic cathinones stability on biological 
samples depends on the pH of the sample, the storage temperature and the 
chemical structure of the cathinone. Differences on the benzene ring, nitrogen 
and phenethylamine backbone [13, 14] may play a role. Tsujika et al. [14] 
showed that the groups attached at the nitrogen atom affect cathinones stability, 
reporting that tertiary amines are more stable. With regard to the ring, 
methylenedioxy-substituted cathinones were more stable probably because did 
not readily reduce to their corresponding alcohols [21, 22], potentially due to 
structural affinity differences to reductive enzymes [22].  
We investigated the stability of 10 synthetic cathinones with different 
chemical structures (position-3’-substituted, N-alkyl-substituted, ring-substituted, 
methylendioxy-substituted and pyrrolidinyl-substituted) in neat OF and preserved 
OF in 2 different buffers (Quantisal and Oral-Eze) stored at 3 temperatures (room 
temperature, 4°C and -20°C) for up to one month and after 3 freeze/thaw cycles. 
In the present study the more stable group was the pyrrolindinyl-substituted 
(tertiary amines), except naphyrone maybe due to the naphthalene group. The 
only synthetic cathinone that was stable in all samples under all storage 
conditions was MPDV, a methylenedioxy and pyrrolindinyl-substittuted derivative. 
MDPV also showed to be stable in blood [10] and urine [3, 10] under different 
storage conditions.  
Synthetic cathinones showed more stability problems in neat samples, 
followed by Oral-Eze, and they were more stable in Quantisal at the different 
storage conditions. The pH of the different pools was tested throughout the 
experiment. Neat OF pools had a pH of 8, Oral-Eze pH 7 and Quantisal pH 6. 
Our data agrees with previous observations in other biological samples, that 
acidic conditions may improve cathinones stability [14].  
The main limitation of the study is that no authentic samples could not be 
analyzed. The most important analyte losses happened at room temperature, 
being -20°C the most stable temperature for the 3 types of samples. The 
cathinones that showed to be more unstable were cathinone and methcathinone, 
but all the groups were significally affected specially at room temperature for all 
types of samples, and in neat OF samples at 4°C too. Only MPDV showed good 
stability under all the storage conditions in any type of samples. These data 
showed that preservation buffer employed and the storage temperature should 
be taken into account to guarantee the stability of the synthetic cathinones in oral 




We developed a sensitive and selective UHPLC-MSMS method for the 
simultaneous determination of 10 synthetic cathinones in preserved OF-
Quantisal samples. We investigated the stability of these drugs in neat OF and 
preserved OF (Quantisal and Oral-Eze) samples stored at 3 temperatures (room 
temperature, 4°C and -20°C) for up to one month. Total losses were observed at 
room temperature in neat and Oral-Eze samples for some analytes. All 
compounds were stable in the 3 types of samples at -20°C. These data add 
important information about NPS stability in OF samples.   
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Table 1. LC-MSMS parameters for 10 synthetic cathinones; multiple reaction 
monitoring (MRM) transitions, retention times, and internal standards. The 
quantifier transition in underlined. 










150>131.95 -26 2.0 Methylone-d3 
Methcathinone 164>131 
164>104.85 
-24 2.1 Methylone-d3 
N-ethylcathinone 178>105.05 
178>117.25 -22 2.3 Methylone-d3 
Methylone 208>159.95 
208>132.05 -19 2.3 Methylone-d3 
Methylone-d3 
211>163.1 
211>135.05 -37 2.3  
Buphedrone 178>131.9 
178>77.2 -14 2.5 Mephedrone-d3 
Mephedrone 178>145 
178>90.95 -23 2.7 Mephedrone-d3 
Mephedrone-d3 
181>163.05 
181>118.9 -15 2.7  
4-MEC 192>144.95 
192>91.05 -25 2.8 Mephedrone-d3 
PVP 232>90.7 
232>77.05 -33 3.2 MDPV-d8 
MDPV 276>175.05 
276>14875 -26 3.3 MDPV-d8 
MDPV-d8 
284>174.95 
284>135 -19 3.3  
Naphyrone 282>141 
















Table 2. Linearity parameters (1-250 ng/ml) for 10 synthetic cathinones in 













Cathinone -0.0005 0.002 0.35 0.04 0.98 0.02 0.75 
Methcathinone -0.0015 0.016 1.51 0.14 0.98 0.02 0.75 
Methylone 0.0039 0.007 0.91 0.06 0.99 0.004 1 
N-ethylcathinone 0.0029 0.007 0.52 0.03 0.99 0.01 1 
Buphedrone 0.0037 0.004 0.49 0.02 0.99 0.005 0.75 
Mephedrone 0.0056 0.005 0.89 0.04 0.99 0.003 1 
4-MEC 0.0093 0.004 0.77 0.04 0.99 0.01 0.75 
PVP 0.0039 0.006 0.62 0.07 0.98 0.02 0.75 
MDPV 0.0055 0.009 1.28 0.05 0.99 0.01 1 































Table 3. Pool intra-day imprecision, total imprecision and accuracy for 10 
synthetic cathinones in oral fluid-Quantisal samples (low QC at 3 ng/mL, high QC 
























Cathinone 5.4 11.0 10.7 13.0 100.3 100.9 
Methcathinone 4.0 10.2 10.9 6.3 95.2 91.4 
Methylone 7.8 6.7 12.3 5.8 100.5 98.9 
N-ethylcathinone 9.1 6.5 7.9 6.3 97.8 93.5 
Buphedrone 9.0 12.5 12.8 8.1 99.1 84.4 
Mephedrone 13.2 11.9 11.8 7.1 97.4 98.7 
4-MEC 8.5 4.7 11.6 6.5 102.0 92.2 
PVP 7.5 7.2 20.7 13.0 115.3 91.2 
MDPV 12.1 6.4 12.4 8.9 104.9 98.2 


















Table 4. Extraction efficiency, process efficiency, and matrix effects for 10 
synthetic cathinones in oral fluid-Quantisal samples (low QC at 3 ng/mL, high QC 





















Cathinone 87.2 97.9 54.6 70.6 -37.4 (15.1) -28.0 (7.3) 
Methcathinone 88.9 105.8 32.2 63.1 -63.8 (11.5) -40.4 (6.7) 
Methylone 99.6 105.8 43.9 66.1 -55.9 (7.1) -37.5 (5.5) 
N-ethylcathinone 102.6 114.8 58.5 76.5 -43.0 (9.2) -33.4 (3.8) 
Buphedrone 100.5 113.1 49.6 81.4 -50.6 (9.2) -28.1 (4.2) 
Mephedrone 101.9 110.5 55.4 75.9 -45.6 (7.8) -31.3 (4.7) 
4-MEC 104.7 112.5 60.0 81.0 -42.7 (8.6) -28.0 (4.1) 
PVP 108.2 109.9 58.0 79.3 -46.4 (12.9) -27.8 (4.3) 
MDPV 106.1 114.1 54.8 73.9 -48.4 (3.7) -35.2 (5.8) 


























Table 5. Stability (%difference) and CV (n=2) for 10 synthetic cathinones in neat oral fluid at room temperature (RT) for 
24h, one week, and one month, at 4°C and -20°C for one week and one month, and after 3 freeze-thaw cycles (3 F/T) at 
2.5 ng/mL (low), and at 150 ng/mL (high). 
 
Analyte Group Analyte RT  
24 h 





























Low High Low High Low High Low High Low High Low High Low High Low High 




























































































































































































































































































































































Table 6. Stability (%difference) and CV (n=2) for 10 synthetic cathinones in oral fluid-Quantisal samples at room 
temperature (RT) for 24h, one week, and one month, at 4°C and -20°C for one week and one month, and after 3 freeze-
thaw cycles (3 F/T) at 2.5 ng/mL (low), and at 150 ng/mL (high). 
 































Low High Low High Low High Low High Low High Low High Low High Low High 


















































































































































































































































































































































Table 7. Stability (%difference) and CV (n=2) for 10 synthetic cathinones in oral fluid-Oral-Eze samples at room 
temperature (RT) for 24h, one week, and one month, at 4°C and -20°C for one week and one month, and after 3 freeze-
thaw cycles (3 F/T) (low at 3 ng/mL, high at 150 ng/mL). 
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Figure 1. Chemical structure of cathinone and synthetic cathinone derivatives 
buphedrone, mephedrone, ethylcathinone, methylone and MDPV.  
                                                        
 
Figure 2. Total ion chromatogram (TIC) of the 10 synthetic cathinones in an oral 







































































Table 1S. Maximum and minimum %difference between fresh and stored sample concentrations (stability), taking into 
account method’s inaccuracy ±15% in the determination of QCs concentrations. These are the results for 10 synthetic 
cathinones in neat oral fluid samples at 2.5 ng/mL (low) and at 150 ng/mL (high). Storage conditions were room 
temperature (RT) for 24h, one week, and one month, at 4°C and -20°C for one week and one month, and after 3 freeze-
thaw cycles (3 F/T). 
 
Analyte Group Analyte RT  
24 h 
max % difference 
min % difference 
RT  
1 week 
max % difference 
min % difference 
RT  
1 month 
max % difference 
min % difference 
4°C 
1 week 
max % difference 
min % difference 
4°C 
1 month 
max % difference 
min % difference 
-20°C 
1 week 
max % difference 
min % difference 
-20°C 
1 month 
max % difference 






Low High Low High Low High Low High Low High Low High Low High Low High 


























































































































































































































































































































































Table 2S. Maximum and minimum %difference between fresh and stored sample concentrations (stability), taking into 
account method’s inaccuracy ±15% in the determination of QCs concentrations. These are the results for 10 synthetic 
cathinones in oral fluid-Quantisal samples at 2.5 ng/mL (low) and at 150 ng/mL (high). Storage conditions were room 
temperature (RT) for 24h, one week, and one month, at 4°C and -20°C for one week and one month, and after 3 freeze-
thaw cycles (3 F/T). 
 
Analyte Group Analyte RT  
24 h 
max % difference 
min % difference 
RT  
1 week 
max % difference 
min % difference 
RT  
1 month 
max % difference 
min % difference 
4°C 
1 week 
max % difference 
min % difference 
4°C 
1 month 
max % difference 
min % difference 
-20°C 
1 week 
max % difference 
min % difference 
-20°C 
1 month 
max % difference 






Low High Low High Low High Low High Low High Low High Low High Low High 


























































































































































































































































































































































Table 3S. Maximum and minimum %difference between fresh and stored sample concentrations (stability), taking into 
account method’s inaccuracy ±15% in the determination of QCs concentrations. These are the results for 10 synthetic 
cathinones in oral fluid-Oral-Eze samples at 2.5 ng/mL (low) and at 150 ng/mL (high). Storage conditions were room 
temperature (RT) for 24h, one week, and one month, at 4°C and -20°C for one week and one month, and after 3 freeze-
thaw cycles (3 F/T). 
 
Analyte Group Analyte RT  
24 h 
max % difference 
min % difference 
RT  
1 week 
max % difference 
min % difference 
RT  
1 month 
max % difference 
min % difference 
4°C 
1 week 
max % difference 
min % difference 
4°C 
1 month 
max % difference 
min % difference 
-20°C 
1 week 
max % difference 
min % difference 
-20°C 
1 month 
max % difference 






Low High Low High Low High Low High Low High Low High Low High Low High 
 Cathinone -49.2 
-7.1 
-37.3 
14.8 
-70.2 
-45.5 
-59.9 
-26.7 
-91.7 
-84.4 
-94.2 
-89.4 
-57.4 
-22.1 
-40.8 
8.4 
-71.9 
-48.5 
-56.1 
-19.7 
-43.7 
3 
-32.7 
23.1 
-48 
-4.8 
-31.2 
26 
-46.2 
-1.5 
-33.5 
21.6 
Methcathi
none 
-26.1 
35.3 
-26.1 
35.3 
-26 
35.5 
-46.6 
-2.3 
-88.8 
-79.4 
-88 
-78.1 
-36.4 
16.4 
-32.5 
23.6 
-54.9 
-17.4 
-43.1 
4.1 
-34.6 
19.7 
-26.5 
34.5 
-35.7 
17.8 
-23.2 
40.5 
-40 
9.9 
-29.6 
28.9 
Position 3’-
substituted 
Buphedro
ne 
-32.5 
23.6 
-24.8 
37.7 
-20.6 
45.3 
-34.6 
19.8 
-66.1 
-38 
-56.9 
-21.1 
-30.9 
26.4 
-29.9 
28.4 
-20.5 
45.6 
-32.6 
23.4 
-19.9 
46.4 
-23.6 
39.8 
-16.2 
53.4 
-27.6 
32.5 
-33.7 
21.4 
-31.1 
26.1 
N-alkyl-
substituted 
N-
ethylcathin
one 
-20.7 
45.1 
-23.9 
39.3 
-41.2 
7.6 
-48.5 
-5.8 
-88 
-78 
-83 
-68.9 
-17.1 
51.7 
-36.2 
16.7 
-52 
-12.2 
-48.7 
-6.1 
-37.1 
15 
-33 
22.6 
-21.7 
43.3 
-31.7 
25 
-21.3 
44.1 
-34.5 
19.8 
4-MEC -27.7 
32.3 
-30.6 
26.9 
-25.6 
36.2 
-31.6 
25.3 
-66.2 
-38.2 
-59.3 
-25.6 
-25 
37.3 
-27.2 
33.3 
-22.5 
41.8 
-21.5 
43.7 
-17.8 
50.4 
-21.4 
43.9 
-17.8 
50.5 
-15.3 
55 
-21.2 
44.3 
-32.1 
24.2 
Ring-
substituted 
Mephedro
ne 
-28 
31.8 
-29.6 
28.9 
-33.1 
22.4 
-40 
9.7 
-72.5 
-49.7 
-71.3 
-47.5 
-29.4 
29.2 
-34.9 
19.2 
-28.2 
31.4 
-38.1 
13.4 
-29.9 
28.4 
-29.7 
28.7 
-22.2 
42.4 
-29.1 
29.8 
-20.4 
45.7 
-31.7 
25 
Methylenediox
y-substituted 
Methylone -16.5 
52.9 
-31.1 
26.2 
-24.6 
38.1 
-38 
13.5 
-49.4 
-7.3 
-56 
-19.5 
-23.4 
40.1 
-35.2 
18.5 
-31.3 
25.7 
-35.7 
17.7 
-11.9 
61.3 
-35.5 
18.1 
-13.9 
57.6 
-25.8 
35.8 
-26.6 
34.4 
-35.9 
17.4 
Pyrrolindinyl-
substituted 
MDPV -22.7 
41.6 
-21.7 
43.4 
-26.5 
34.6 
-24 
39.1 
-32.2 
24 
-27.8 
32.2 
-27.8 
32.2 
-30.9 
26.5 
-25.9 
35.7 
-20.4 
45.7 
-28.8 
30.4 
-22.3 
42.3 
-15.2 
55.2 
-19.6 
47.1 
-25.2 
36.9 
-33 
22.7 
Naphyron
e 
-40.7 
8.6 
-28.7 
30.4 
-69.2 
-43.5 
-63.2 
-32.6 
-100 
-100 
-97.1 
-94.6 
-45 
0.7 
-33.5 
21.7 
-53.4 
-14.8 
-41 
8 
-39.5 
10.7 
-28.1 
31.6 
-18.5 
49.2 
-16.8 
52.3 
-42.5 
5.3 
-28.4 
31 
PVP -23.2 
40.6 
-33 
22.7 
-29.6 
28.9 
-43.3 
3.8 
-47.5 
-3.9 
-39.4 
10.9 
-29.6 
28.9 
-37.2 
15 
-13.3 
58.7 
-30.7 
26.8 
-21.5 
43.7 
-32.1 
24.3 
-10.1 
64.5 
-11.1 
62.8 
-17.4 
51.2 
23.9 
39.3 
 
 
 
